Unbiased Analysis of Today's Healthcare Issues
The Hill reports today that: The Biden administration is rolling out a framework to enforce the government’s march-in authorities on drugs developed with taxpayer dollars, saying if drugmakers refuse to make their products “reasonably” available, then the government is prepared to give other companies license to produce those drugs at a lower cost…. If the company refuses…
That is the title of a new working paper written by myself, any my FTI Consulting colleagues Sabiha Quddus and Suhail Thahir. The abstract is below. Some policymakers have called for weakening of intellectual property protections for vaccines and other pharmaceutical products, with the aim to reduce the price and improve access to existing medical…
That is the title of an FTI White Paper published this year where I was a co-author alongside Antoine Mialhe, Sabiha Quddus, Anne-Sophie Deman, Suhail Thahir and Agnes Sipiczki. The role of Intellectual property (IP) in the development of COVID-19 vaccines and therapeutics became a central tenant in discussions on how to ensure access to…
A paper from Nayak et al. (2021) in JAMA Internal Medicine describes how public-private partnerships have helped bring new biologic drugs to market. Using data on new biologic drugs approved by the FDA’s Center for Drug Evaluation and Reseach (CDER) and US patent office data, the authors find that: Twenty-nine drugs (42%) showed evidence of…
That is the title of a 2016 NBER chapter by Heidi Williams and the subtitle is “Evidence from Health Care Markets“. Economic theory back to Nordhaus (1969) predicts that intellectual property rights increase the incentive for firms to invest in research and development and likely this would lead to more innovation. Proving these empirically, however,…
Consider the case of two drugs, Drug A and Drug B. Both drugs treat patients with the same disease. Further, assume they are close substitutes. When Drug A loses it’s patent and generics can enter the market, one would expect Drug A’s market share (brand + generic) to rise. In fact, Drug A’s market share…
An interesting article by Charles Silver and David A. Hyman argues that we should do away with patents for pharmaceuticals and move to a prize based system. They write in Vox: A well-designed prize regime would lower drug prices by eliminating drug monopolies, yet it would also create the necessary incentives for innovation, including incentives to…
Below are some excerpts from seminal papers examining how changes in reimbursement or market size affect pharmaceutical innovation. Acemoglu and Lin (2004): Our estimates suggest that a 1 percent increase in the size of the potential market for a drug category leads to a 6 percent increase in the total number of new drugs entering the…
Currently, robot-assisted surgery today is dominated by the da Vinci Surgical System. The device is highly regarded, but is heavy (weighs half a ton) and expensive ($1.8m). Plus it uses proprietary software, which means that physicians and engineers not associated with da Vinci cannot alter its operating system. Change is on the horizon, however. “None…
Planet Money has a very interesting article about software patents and companies who exist for the sole purpose of buying these assets and suing other companies. Computer programmers themselves don’t even like their own patents. In previous posts, I’ve made arguments for limiting patents for pharmaceuticals and the cases for software patents is even stronger.…